A New Therapeutic Strategy for Type 2 Diabetes - Free CE ...

More documents

Recommendations

Info

Case Study• Susan is 47-year-old Native American woman whosigns up for glucose screening in your pharmacy.• Medical History: gestational diabetes 13 yrs ago withonly child, hypertension• Medications: HCTZ 25 mg qd• Family History: 62-year-old father developed type 2diabetes at age 50• Fasting glucose = 105 mg/dl• HT: 5'6”, WT: 188 lbs (BMI: 30.3)• BP: 142/86 mm Hg©MedOutcomes, Inc. 2008
Natural History of Type 2 DiabetesPrediabetes/IGT/IFGT2DMPostprandial glucoseGlucoseFasting glucose126 mg/dl-10 -5 0 5 10 15 20 25 30RelativeFunction100%Insulin levelBeta-cell functionInsulin resistance —hepatic and peripheral–10 –5 0 5 10 15 20 25 30Years from Diabetes DiagnosisIGT=impaired glucose tolerance; IFG=impaired fasting glucose.Diabetes Care 1992;15:815-819.
Page 1 and 2: Modulating the Incretin System:A Ne
Page 3 and 4: The Diabetes Epidemic• 8.0% of US
Page 5: Normal Glucose HomeostasisGlucagon(
Page 9 and 10: Other fundamental defects inType 2
Page 11: Unmet Pathophysiologic Needs in Typ
Page 14 and 15: Recent Trials in Type 2 DM• ACCOR
Page 16 and 17: Mean Plasma GlucoseA1C (%) Mean pla
Page 18 and 19: GOOD GLYCEMIC CONTROL: ACRITICAL BU
Page 20 and 21: Patients With Type 2 Diabetes May S
Page 22 and 23: Incretin Hormones• Peptides produ
Page 24 and 25: GLP-1 Actions in HumansUpon ingesti
Page 26 and 27: Incretin-Based Therapies• Increti
Page 28 and 29: Exenatide (Byetta ® )What to Do Ab
Page 31 and 32: Improvement in HOMA-BFrom Baseline
Page 33: Sitagliptin (Januvia ® )• Orally
Page 36 and 37: ©MedOutcomes, Inc. 2008• Adverse
Page 38 and 39: Vildagliptin (Galvus ® )• Indica
Page 40 and 41: GLP-1 Mimetics versus DPP-IVInhibit
Page 42 and 43: Who might benefit most fromincretin
Page 44: To Sum It All Up• Incretin hormon

A New Therapeutic Strategy for Type 2 Diabetes - Free CE ...

Create successful ePaper yourself

Delete template?

Save as template?